检索结果-南通市图书馆

High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy

引用

Nano Research 2021年第11期14卷 3913-3920页

作者： Wei Jiang Han Zhou Qin Wang Ziqi Chen Wang Dong Zixuan Guo Yong Li Wei Zhao Meixiao Zhan Yucai Wang Ligong Lu Zhuhai Interventional Medical Center Zhuhai Precision Medical CenterZhuhai People’s Hospital(Zhuhai Hospital Affiliated with Jinan University)Zhuhai519000China Division of Molecular Medicine Hefei National Laboratory for Physical Sciences at Microscalethe CAS Key Laboratory of Innate Immunity and Chronic DiseaseSchool of Life SciencesUniversity of Science and Technology of ChinaHefei230026China

Tumor cells undergoing immunogenic cell death (ICD) have emerged as an in situ therapeutic vaccine helping to activate a persistent anti-tumor response. Several chemotherapeutic agents have been demonstrated to induce ICD, however accompanied with severe adverse effects in the clinic, weakening its immune responses. Herein, to elicit an intensive ICD while minimizing the systemic toxicity, we introduce a tumor targeting peptide modified bortezomib (BTZ) loading nanomedicine (i-NPBTZ) for the efficient delivery and controlled release of BTZ in tumors. This system is constructed by conjugating BTZ to PEGylated polyphenols via a pH-sensitive covalent boronate-phenol bond that allows them to self-assemble into nanovesicles in neutral condition with high drug loading efficiency. Once accumulated in acidic environment, BTZ-phenolic network is disassembled and thereby accelerates the release of BTZ from nanocarriers. The released BTZ selectively kill tumor cells with a concomitant evocation of tumor-specific cytotoxic T cells by triggering ICD in vivo. This can finally lead to an extended tumor ablation and prevention of distant metastasis in a syngeneic tumor mouse model, while reducing the systemic toxicity of BTZ. In general, our system offers a novel concept with clinical potential to exploit ICD for potentiating tumor immunotherapy and also provides an excellent example of the application of polymer-drug interaction for efficient drug delivery and controllable release.

关键词： bortezomib boronate-phenolic network pH-responsiveness immunogenic cell death cancer immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy

引用

Cellular & Molecular Immunology 2012年第1期9卷 45-53页

作者： Thanh-Nhan Nguyen-Pham Deok-Hwan Yang Truc-Anh Thi Nguyen Mi-Seon Lim Cheol Yi Hong Mi-Hyun Kim Hyun Ju Lee Youn-Kyung Lee Duck Cho Soo-Young Bae Jae-Sook Ahn Yeo-Kyeoung Kim Ik-Joo Chung Hyeoung-Joon Kim Je-Jung Lee Research Center for cancer immunotherapy Chonnam National University Hwasun HospitalJeollanamdoKorea Department of Hematology-Oncology Chonnam National University Hwasun HospitalJeollanamdoKorea Vaxcell-Bio Therapeutics JeollanamdoKorea The Brain Korea 21 Project Center for Biomedical Human Resources at Chonnam National UniversityGwangjuKorea

Dendritic cell(DC)-based vaccines continue to be considered an attractive tool for cancer *** require an additional signal from the environment or other immune cells to polarize the development of immune responses toward T helper 1(Th1)or Th2 *** play a role in natural killer(NK)cell activation,and NK cells are also able to activate and induce the maturation of *** investigated the types of NK cells that can induce the maturation and enhanced function of DCs and the conditions under which these interactions *** that were activated by resting NK cells in the presence of inflammatory cytokines exhibited increased expression of several costimulatory molecules and an enhanced ability to produce *** cell-stimulated DCs potently induced Th1 polarization and exhibited the ability to generate tumor antigen-specific cytotoxic T lymphocyte *** data demonstrate that functional DCs can be generated by coculturing immature DCs with freshly isolated resting NK cells in the presence of Toll-like receptor agonists and proinflammatory cytokines and that the resulting DCs effectively present antigens to induce tumor-specific T-cell responses,which suggests that these cells may be useful for cancer immunotherapy.

关键词： cancer immunotherapy dendritic cells natural killer cells signal

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Applying artificial intelligence for cancer immunotherapy

引用

Acta Pharmaceutica Sinica B 2021年第11期11卷 3393-3405页

作者： Zhijie Xu Xiang Wang Shuangshuang Zeng Xinxin Ren Yuanliang Yan Zhicheng Gong Department of Pathology Xiangya HospitalCentral South UniversityChangsha 410008China Department of Pharmacy Xiangya HospitalCentral South UniversityChangsha 410008China Institute for Rational and Safe Medication Practices National Clinical Research Center for Geriatric DisordersXiangya HospitalCentral South UniversityChangsha 410008China Center for Molecular Medicine Xiangya HospitalKey Laboratory of Molecular Radiation Oncology of Hunan ProvinceCentral South UniversityChangsha 410008China

Artificial intelligence(AI)is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention,such as machine learning;this technology is revolutionizing and reshaping *** has considerable potential to perfect health-care systems in areas such as diagnostics,risk analysis,health information administration,lifestyle supervision,and virtual health *** terms of immunotherapy,AI has been applied to the prediction of immunotherapy responses based on immune signatures,medical imaging and histological *** features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy,optimizing treatment planning,predicting outcomes of care and reducing human resource *** this review,we present the details of AI and the current progression and state of the art in employing AI for cancer ***,we discuss the challenges,opportunities and corresponding strategies in applying the technology for widespread clinical ***,we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future.

关键词： Artificial intelligence cancer immunotherapy Machine learning Diagnostics

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy

引用

Acta Pharmaceutica Sinica B 2021年第10期11卷 3244-3261页

作者： Hao Ren Jiahui Yong Qingqing Yang Zhen Yang Zhangya Liu Yan Xu Hao Wang Xing Jiang Wenjun Miao Xueming Li School of Pharmaceutical Science Nanjing Tech UniversityNanjing 211816China School of Nursing Nanjing University of Chinese MedicineNanjing 210023China

Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death(ICD)to provoke a robust immune response for metastasis ***,a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumor penetration and synergistic therapy of starvation,chemodynamic(CDT)and photothermal *** Fe S-GOx nanodots were synthesized with glucose oxidase(GOx)as template and induced by paclitaxel(PTX)to form self-assembling Fe S-GOx@PTX(FGP)via hydrophobic *** accumulated at tumor sites,FGP disassembles to smaller Fe S-GOx for enhanced deep tumor *** maintains high enzymatic activity to catalyze glucose with assistant of oxygen to generate hydrogen peroxide(H2O2)as starvation *** reaction involving the regenerated H_(2)O_(2) in turn produced more hydroxyl radicals for enhanced *** near-infrared laser at 808 nm,FGPs displayed pronounced tumor inhibition in vitro and in vivo by the combination *** consequent increased exposure to calreticulin amplified ICD and promoted dendritic cells *** combination with anti-CTLA4 checkpoint blockade,FGP can absolutely eliminate primary tumor and avidly inhibit distant tumors due to the enhanced intratumoral infiltration of cytotoxic T *** work presents a promising strategy for primary tumor and metastasis inhibition.

关键词： Fe S-based cascade bioreactor Glucose oxidase Tumor penetration Synergistic therapy ICD amplifier cancer immunotherapy Metastasis inhibition

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigenspecific CD8^+ T cell responses

引用

Acta Pharmaceutica Sinica B 2020年第6期10卷 1047-1060页

作者： Wenjie Zhai Xiuman Zhou Hongfei Wang Wanqiong Li Guanyu Chen Xinghua Sui Guodong Li Yuanming Qi Yanfeng Gao School of Life Sciences Zhengzhou UniversityZhengzhou 450001China School of Pharmaceutical Sciences(Shenzhen) Sun Yat-sen UniversityGuangzhou 510006China

PD-1 and CTLA-4 antibodies offer great hope for cancer ***,many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune *** combination of checkpoint blockers has been proposed to increase the response ***,antibody drugs have disadvantages such as inclined to cause immune-related adverse events and infiltration *** this study,we developed a cyclic peptide C25 by using Ph.D.-C7C phage display technology targeting *** a result,C25 showed a relative high affinity with human LAG-3 protein and could effectively interfere the binding between LAG-3 and HLA-DR(MHC-II).Additionally,C25 could significantly stimulate CD8^+T cell activation in human *** results also demonstrated that C25 could inhibit tumor growth of CT26,B16 and B 16-OVA bearing mice,and the infiltration of CD8^+T cells was significantly increased while FOXP3^+Tregs significantly decreased in the tumor ***,the secretion of IFN-γby CD8^+T cells in spleen,draining lymph nodes and especially in the tumors was ***,we exploited T cells depletion models to study the anti-tumor mechanisms for C25 peptide,and the results combined with MTT assay confirmed that C25 exerted anti-tumor effects via CD8+T cells but not direct *** conclusion,cyclic peptide C25 provides a rationale for targeting the immune checkpoint,by blockade of LAG-3/HLA-DR interaction in order to enhance anti-tumor immunity,and C25 may provide an alternative for cancer immunotherapy besides antibody drugs.

关键词： LAG-3 Phage display Cyclic peptide Immune checkpoint blockade CD8^+T cell cancer immunotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition

引用

Chinese Chemical Letters 2021年第6期32卷 1929-1936页

作者： Jing Gao Hanwu Zhang Fengqi Zhou Bo Hou Meiwan Chen Zhigang Xie Haijun Yu State Key Laboratory of Drug Research&Center of Pharmaceutics Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China Department of Medical Ultrasound Shanghai Tenth People's HospitalUltrasound Research and Education InstituteTongji University School of MedicineTongji University Cancer CenterShanghai 200072China Peking University Shenzhen Institute Shenzhen 518055China State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical SciencesUniversity of MacaoMacao 999078China State Key Laboratory of Polymer Physics and Chemistry Changchun Institute of Applied ChemistryChinese Academy of SciencesChangchun 130022China

Cyclin-dependent kinases 4 and 6 inhibitors(CDK4/6i)have been demonstrated to trigger antitumor immunity for tumor ***,the therapeutic performance of CDK4/6i-meadiated cancer immunotherapy was impaired by the immunosuppressive tumor microenvironment(ITM)due to overexpression of programmed death ligand 1(PD-L1)on the surface of cancer cell *** improve the immunotherapeutic performance of CDK4/6i,we herein developed endosomal acidactivatable micelleplex for si RNA delivery and PD-L1 knockdown in the tumor cells in vitro and in *** further demonstrated that the combination of PD-L1 knockdown and CDK4/6 inhibition facilitated intratumoral infiltration of cytotoxic T lymphocytes(CTLs),and elicited protective immune response and efficiently suppressed tumor growth in *** study revealed the importance of molecular design of the micelleplex for highly efficient si RNA delivery,which might provide a novel insight for RNAi-based cancer immunotherapy.

关键词： cancer immunotherapy siRNA delivery Acid-activatible micelleplex CDK4/6 inhibitor PD-L1 knockdown

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy

引用

Science China(Life Sciences) 2021年第4期64卷 548-562页

作者： Wenjie Zhai Xiuman Zhou Mingxia Zhai Wanqiong Li Yunhui Ran Yixuan Sun Jiangfeng Du Wenshan Zhao Lingxiao Xing Yuanming Qi Yanfeng Gao School of Life Sciences Zhengzhou UniversingZhengzhou 450001China School of Pharmacenutical Sciences(Shenzhen) Sun Yar-sen UniversiyShenzhen 518107.China Deparment of Pathology Hebei Medical University Shijazhuang 050017China

The interaction of PD-1/PD-L1 allows tumor cells to escape from immune *** success of the antibody drugs has proven that blockade of PD-1/PD-L1 pathway is a promising strategy for cancer ***,we developed a cyclic peptide C8 by using Ph.D.-C7 C phage display technology.C8 showed high binding affinity with h PD-1 and could effectively interfere the interaction of PD-1/***,C8 could stimulate CD8^(+)T cell activation in human peripheral blood mononuclear cells(PBMCs).We also observed that C8 could suppress tumor growth in CT26 and B16-OVA,as well as anti-PD-1 antibody resistant B16 mouse ***8^(+)T cells infiltration significantly increased in tumor microenvironment,and IFN-γsecretion by CD8^(+)T cells in draining lymph nodes also ***,we exploited T cells depletion models and confirmed that C8 exerted anti-tumor effects via activating CD8^(+)T cells dependent *** interaction model of C8 with h PD-1 was simulated and confirmed by alanine *** conclusion,C8 shows anti-tumor capability by blockade of PD-1/PD-L1 interaction,and C8 may provide an alternative candidate for cancer immunotherapy.

关键词： PD-1/PD-L1 cancer immunotherapy immune checkpoint blockade cyclic peptide phage display CD8~+T cell

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Nano-bio interfaces effect of two-dimensional nanomaterials and their applications in cancer immunotherapy

引用

Acta Pharmaceutica Sinica B 2021年第11期11卷 3447-3464页

作者： Zhongmin Tang Yufen Xiao Na Kong Chuang Liu Wei Chen Xiangang Huang Daiyun Xu Jiang Ouyang Chan Feng Cong Wang Junqing Wang Han Zhang Wei Tao International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology of Ministry of Education Institute of Microscale OptoelectronicsShenzhen UniversityShenzhen 518060China Center for Nanomedicine and Department of Anesthesiology Brigham and Women's HospitalHarvard Medical SchoolBostonMA 02115USA School of Pharmaceutical Sciences(Shenzhen) Sun Yat-sen UniversityGuangzhou 510275China

The field of two-dimensional(2D)nanomaterial-based cancer immunotherapy combines research from multiple subdisciplines of material science,nano-chemistry,in particular nanobiological interactions,immunology,and medicinal *** importantly,the"biological identity"of nanomaterials governed by bio-molecular corona in terms of bimolecular types,relative abundance,and conformation at the nanomaterial surface is now believed to influence blood circulation time,biodistribution,immune response,cellular uptake,and intracellular trafficking.A better understanding of nano-bio interactions can improve utilization of 2D nano-architectures for cancer immunotherapy and immunotheranostics,allowing them to be adapted or modified to treat other immune dysregulation syndromes including autoimmune diseases or inflammation,infection,tissue regeneration,and *** manuscript reviews the biological interactions and immunotherapeutic applications of 2D nanomaterials,including understanding their interactions with biological molecules of the immune system,summarizes and prospects the applications of 2D nanomaterials in cancer immunotherapy.

关键词： Two-dimensional nanomaterials Nano-bio interactions Immune system Antigens Adjuvants Modulators cancer immunotherapy Biosensing

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy

引用

Acta Pharmaceutica Sinica B 2020年第11期10卷 2054-2074页

作者： Yuefei Zhu Xiangrong Yu Soracha D.Thamphiwatana Ying Zheng Zhiqing Pang Department of Biomedical Engineering Columbia UniversityNew YorkNY 10027USA Key Laboratory of Smart Drug Delivery School of PharmacyFudan UniversityMinistry of EducationShanghai 201203China Department of Medical Imaging Zhuhai People’s HospitalZhuhai Hospital Affiliated with Jinan UniversityZhuhai 519000China Department of Biomedical Engineering Faculty of EngineeringMahidol UniversityNakhon Pathom 73170Thailand State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical SciencesUniversity of MacaoMacao 999078China

cancer immunotherapy has veered the paradigm of cancer *** recent advances in immunotherapy for improved antitumor efficacy,the complicated tumor microenvironment(TME)is highly immunosuppressive,yielding both astounding and unsatisfactory clinical *** this regard,clinical outcomes of currently available immunotherapy are confined to the varied immune systems owing in large part to the lack of understanding of the complexity and diversity of the immune context of the *** advanced designs of nanomedicines could still not fully surmount the delivery barriers of the *** immunosuppressive TME may even dampen the efficacy of antitumor ***,some nanotechnology-related strategies have been inaugurated to modulate the immunosuppressive cells within the tumor immune microenvironment(TIME)for robust immunotherapeutic *** this review,we will highlight the current understanding of the immunosuppressive TIME and identify disparate subclasses of TIME that possess an impact on immunotherapy,especially those unique classes associated with the immunosuppressive *** immunoregulatory cell types inside the immunosuppressive TIME will be delineated along with the existing and potential approaches for immunosuppressive cell *** introducing the various strategies,we will ultimately outline both the novel therapeutic targets and the potential issues that affect the efficacy of TIME-based nanomedicines.

关键词： cancer immunotherapy Nanomedicine Tumor immunosuppressive microenvironment Drug delivery

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Polysaccharide-based nanomedicines for cancer immunotherapy:A review

引用

Bioactive Materials 2021年第10期6卷 3358-3382页

作者： Yujun Zeng Yufan Xiang Ruilong Sheng Helena Tomás João Rodrigues Zhongwei Gu Hu Zhang Qiyong Gong Kui Luo Huaxi MR Research Center(HMRRC) Department of RadiologyDepartment of NeurosurgeryFunctional and Molecular Imaging Key Laboratory of Sichuan ProvinceNational Clinical Research Center for GeriatricsWest China HospitalSichuan UniversityChengdu610041China Research Unit of Psychoradiology Chinese Academy of Medical SciencesChengdu610041China CQM-Centro de Quimica da Madeira MMRGUniversidade da MadeiraCampus da Penteada9000-390FunchalMadeiraPortugal Amgen Bioprocessing Centre Keck Graduate InstituteClaremontCA91711USA

cancer immunotherapy is an effective antitumor approach through activating immune systems to eradicate tumors by ***,direct administration of“naked”immunotherapeutic agents(such as nucleic acids,cytokines,adjuvants or antigens without delivery vehicles)often results in:(1)an unsatisfactory efficacy due to suboptimal pharmacokinetics;(2)strong toxic and side effects due to low targeting(or off-target)*** overcome these shortcomings,a series of polysaccharide-based nanoparticles have been developed to carry immunotherapeutics to enhance antitumor immune responses with reduced toxicity and side *** are a family of natural polymers that hold unique physicochemical and biological properties,as they could interact with immune system to stimulate an enhanced immune *** structures offer versatility in synthesizing multifunctional nanocomposites,which could be chemically modified to achieve high stability and bioavailability for delivering therapeutics into tumor *** review aims to highlight recent advances in polysaccharide-based nanomedicines for cancer immunotherapy and propose new perspectives on the use of polysaccharide-based immunotherapeutics.

关键词： Polysaccharides Drug delivery systems Nanomedicines cancer immunotherapy Anticancer efficacy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：